Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viridian Therapeutics
Biotech
Viridian eye disease phase 3 hits, advancing push to rival Amgen
With Tepezza on the market, the data leave scope to question whether the biotech has done enough to differentiate its asset and unseat the incumbent.
Nick Paul Taylor
Sep 10, 2024 8:10am
Longtime BioMarin CEO hands off baton—Chutes & Ladders
Nov 3, 2023 9:30am
Viridian looks to beat Horizon's Tepezza in thyroid eye disease
Jul 10, 2023 4:01pm
